Xenetic Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Royalty Revenue from Takeda Sublicense Quarterly806.9K
Cash and Cash Equivalents Quarterly7.3M
Net Loss Quarterly-456.4K
Watch Items
- IND-enabling activities and Phase 1 clinical trial initiation for systemic DNase programTrigger: Filing of Investigational New Drug (IND) application with the FDAAction: Evaluate clinical trial design, projected R&D expenditure, and timeline to first-in-human dosing.
- Strategic alternatives evaluation processTrigger: Announcement of a definitive agreement, merger, acquisition, or termination of the reviewAction: Assess the impact of any transaction on shareholder value, pipeline focus, and corporate structure.
- Cash runway and capital requirementsTrigger: Cash balance falling below $5.0 millionAction: Re-evaluate financing options, potential dilution risk, or strategic partnership opportunities to secure non-dilutive funding.
Research as of 20 Jun 2026